Please login to the form below

Not currently logged in
Email:
Password:

Valeant to buy Afexa

Canada-based drugmaker Valeant Pharmaceuticals is to purchase Afexa Life Sciences for around C$76m in the latest of a series of major acquisitions

Canada-based drugmaker Valeant Pharmaceuticals is to purchase Afexa Life Sciences for around C$76m.

It is the latest in a series of major acquisitions during 2011 that has seen Valeant take ownership of Lithuanian speciality firm AB Sanitas, Swiss company PharmaSwiss SA and Sanofi's dermatology unit, Dermik.

The company was also involved in a hostile takeover bid for Cephalon, and recent reports have suggested Valeant is keen to acquire Swedish pharmaceutical firm Meda as well as Medicis Pharmaceutical.

The Afexa acquisition will see Valeant take control of a company with annual revenues of around C$40m and gain the rights to brands including Cold-FX and Coldsore-FX.

J Michael Pearson, chairman and CEO of Valeant, said the purchase would deliver "significant benefits" to the company's customers, and would develop the company's over-the-counter (OTC) profile.

Pearson added: "Afexa's product line, combined with our portfolio from VitalScience, including dermaglow, and our recent Canadian launch of CeraVe, will provide the critical mass we need in the OTC market and should provide Valeant Canada with another platform for growth."

Full details of the offer will be mailed to company shareholders by September 9, 2011.

31st August 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Nobull Communications

Switched on Creative Communications. With an encyclopedic working knowledge of pharmaceutical industry rules and regulations, we create dynamic, intuitive and...

Latest intelligence

Is the pharma business model ready for precision medicine?
Precision medicine promises to revolutionise patient outcomes and reduce costs for industry but is pharma ready for it? Blue Latitude Health co-founder Head of Strategy Fred Bassett explores the challenges...
ABPI2018
The NHS and ABPI at 70: inching closer to the triple win
The NHS and UK pharma’s ABPI both turn 70 this year. After years of transactional relationships, there’s a will to work more closely - but friction on prices and value...
What pharma marketers can learn from behavioural science
Pharma behavioural science and traditional emotional marketing create a powerful mix of techniques that have impact on real lives....

Infographics